TG Therapeutics, Inc. (LON:0VGI)
37.11
+9.04 (32.21%)
At close: Oct 1, 2025
TG Therapeutics Revenue
TG Therapeutics had revenue of $141.15M USD in the quarter ending June 30, 2025, with 92.13% growth. This brings the company's revenue in the last twelve months to $454.07M, up 30.96% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$454.07M
Revenue Growth
+30.96%
P/S Ratio
11.03
Revenue / Employee
$1.34M
Employees
338
Market Cap
3.66B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
TG Therapeutics News
- 4 weeks ago - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment - GlobeNewsWire
- 4 weeks ago - TG Therapeutics Breaks Above 200-Day Moving Average - Bullish for TGTX - Nasdaq
- 5 weeks ago - Interesting TGTX Put And Call Options For May 2026 - Nasdaq
- 5 weeks ago - TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News - GuruFocus
- 6 weeks ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting - GlobeNewsWire
- 6 weeks ago - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment - GlobeNewsWire
- 7 weeks ago - TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire